Cingulate (CINGW) Expected to Release Earnings on Tuesday

Cingulate (NASDAQ:CINGW) is expected to be posting its results before the market opens on Tuesday, August 18th. Analysts expect the company to announce earnings of ($0.6250) per share and revenue of $0.1670 million for the quarter.

Cingulate Stock Performance

NASDAQ:CINGW opened at $0.01 on Tuesday. The firm’s fifty day simple moving average is $0.02 and its 200 day simple moving average is $0.03. Cingulate has a twelve month low of $0.01 and a twelve month high of $0.12.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.